CLDX
Celldex Therapeutics Inc.
$33.87
Earnings Summary
Revenue | $0.17Mn |
Net Profits | $-23.05Mn |
Net Profit Margins | -13247.13% |
Highlights
Celldex Therapeutics Inc.’s revenue fell -74.6% since last year same period to $0.17Mn in the Q1 2022. On a quarterly growth basis, Celldex Therapeutics Inc. has generated -47.9% fall in its revenue since last 3-months.
Celldex Therapeutics Inc.’s net profit fell -39.38% since last year same period to $-23.05Mn in the Q1 2022. On a quarterly growth basis, Celldex Therapeutics Inc. has generated -14.4% fall in its net profits since last 3-months.
Celldex Therapeutics Inc.’s net profit margin fell -448.69% since last year same period to -13247.13% in the Q1 2022. On a quarterly growth basis, Celldex Therapeutics Inc. has generated -119.6% fall in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Celldex Therapeutics Inc. post its latest quarter earnings
EPS Estimate Current Quarter | -0.51 |
EPS Estimate Current Year | -0.51 |
Highlights
Celldex Therapeutics Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.51 - a -13.33% fall from last quarter’s estimates.
Celldex Therapeutics Inc.’s earning per share (EPS) estimates for the current year stand at -0.51.
Key Ratios
Key ratios of the Celldex Therapeutics Inc. post its Q1 2022 earnings
Earning Per Share (EPS) | -0.49 |
Return on Assets (ROA) | -0.19 |
Return on Equity (ROE) | -0.36 |
Dividend Per Share (DPS) | 0 |
Highlights
Celldex Therapeutics Inc.’s earning per share (EPS) fell -16.67% since last year same period to -0.49 in the Q1 2022. This indicates that the Celldex Therapeutics Inc. has generated -16.67% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Celldex Therapeutics Inc.’s return on assets (ROA) stands at -0.19.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Celldex Therapeutics Inc.’s return on equity (ROE) stands at -0.36.
Celldex Therapeutics Inc. declared 0 dividend per share during the earnings announcement for Q1 2022.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2022-05-05 | -0.45 | -0.49 | -8.89% |
Company Information
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly effect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.
Organisation | Celldex Therapeutics Inc. |
Headquarters | Hampton, New Jersey, US |
Employees | 124 |
Industry | Health Technology |
CEO | Anthony Marucci |